INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
INmune Bio Inc. (NASDAQ: INMB) presented important findings at The 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany. The data shows that XPro™, by neutralizing soluble TNF, promotes remyelination in the cuprizone model by increasing astrocyte and microglia activation responses.
Key findings include:
- Astrocytes are rapidly activated in response to demyelination
- Preventing soluble TNF and TNFR1 function in mice mirrors XPro™'s effects
- Traditional biomarkers of astroglial and microglial activation (GFAP and Iba1) are increased in myelin-promoting glial cells
These results challenge the current belief that decreased glial activation is required for remyelination, suggesting that immunosuppressive therapies may not aid brain repair in neurologic diseases.